https://cessatech.com/news/ 2026-02-27T07:29:44+00:00 https://cessatech.com/cessatech-a-s-receives-approval-for-ipo-listing-and-publishes-prospectus/ 2020-12-07T11:03:48+00:00 https://cessatech.com/wp-content/uploads/2020/11/CT_release-e1604671792323.png https://cessatech.com/news-press-3/ 2020-12-07T11:03:54+00:00 https://cessatech.com/wp-content/uploads/2020/09/BoD.jpg https://cessatech.com/cessatechs-ipo-of-units-significantly-oversubscribed/ 2020-12-07T12:57:55+00:00 https://cessatech.com/wp-content/uploads/2020/09/AdobeStock_360221622_low2-3-scaled-e1599420963172.jpeg https://cessatech.com/year-end-report-q4-2020-on-track-and-accelerating-clinical-activities/ 2021-02-11T07:13:21+00:00 https://cessatech.com/wp-content/uploads/2021/02/Q4-2020.png https://cessatech.com/supporting-save-the-children/ 2021-02-19T12:56:09+00:00 https://cessatech.com/wp-content/uploads/2021/02/E_SIGNATUR_UK.jpg https://cessatech.com/ny-forskning-barn-bor-fa-smartlindring-vid-vaccinationer-och-injektioner/ 2021-02-23T05:52:29+00:00 https://cessatech.com/wp-content/uploads/2021/02/Picture-1.png https://cessatech.com/facts-example-3/ 2021-02-23T05:55:11+00:00 https://cessatech.com/wp-content/uploads/2020/09/gabriel-baranski-vGICUyYW2CE-unsplash-1-1.jpg https://cessatech.com/wp-content/uploads/2020/09/AdobeStock_HAND-scaled-1.jpeg https://cessatech.com/facts-example-2/ 2021-02-23T05:56:06+00:00 https://cessatech.com/wp-content/uploads/2020/09/child-taking-pill-600x300-1-e1604402229815.jpg https://cessatech.com/wp-content/uploads/2020/09/SeventyFour842481112.jpg https://cessatech.com/facts-example-1/ 2021-02-26T03:59:20+00:00 https://cessatech.com/wp-content/uploads/2020/09/BornAldreMedicin.jpeg https://cessatech.com/wp-content/uploads/2020/09/Screenshot-2020-09-06-at-14.19.46.png https://cessatech.com/favourable-data-%E2%80%A6try-safety-study/ 2021-03-04T08:30:03+00:00 https://cessatech.com/wp-content/uploads/2021/03/RSS-e1614798915769.png https://cessatech.com/cessatech-as-is-awarded-best-medical-treatment-ipo-nordics-in-2020-by-independent-editorial/ 2021-03-09T04:59:06+00:00 https://cessatech.com/wp-content/uploads/2021/03/CFI_award.png https://cessatech.com/behov-for-storre-sikkerhed-omkring-medicin-til-born-og-unge-i-danmark/ 2021-03-18T15:03:08+00:00 https://cessatech.com/wp-content/uploads/2021/03/pige-medicineres-470x314-1.jpeg https://cessatech.com/cessatech-reports-first-subject-dosed-in-bioavailability-trial-of-lead-product-candidate/ 2021-03-24T08:27:15+00:00 https://cessatech.com/wp-content/uploads/2021/03/Trial0204.png https://cessatech.com/first-quarter-report-q1-2021-one-down-two-to-go-of-the-major-milestones-of-2021/ 2021-04-19T06:07:36+00:00 https://cessatech.com/wp-content/uploads/2021/04/Q1-icon-1.png https://cessatech.com/cessatech-as-is-awarded-ipo-of-the-year-2020-by-independent-editorial-affarsvarlden/ 2021-05-14T07:17:07+00:00 https://cessatech.com/wp-content/uploads/2021/05/Screenshot-2021-05-14-at-08.57.36.png https://cessatech.com/last-subject-dosed-in-bioavailability-trial-0204-of-lead-product-candidate/ 2021-05-31T05:59:20+00:00 https://cessatech.com/wp-content/uploads/2021/03/Trial0204.png https://cessatech.com/cessatech-announces-new-chairman-of-the-board-getting-ready-for-the-pivotal-studies/ 2021-06-29T06:15:36+00:00 https://cessatech.com/wp-content/uploads/2021/06/Screenshot-2021-06-28-at-22.37.41.png https://cessatech.com/second-quarter-report-q2-2021-planning-for-the-pivotal-trials/ 2021-08-19T06:04:03+00:00 https://cessatech.com/wp-content/uploads/2021/08/Q2_2021.png https://cessatech.com/cessatech-reports-first-patient-dosed-in-pharmacokinetic-trial-in-children-of-lead-product-candidate/ 2021-08-20T06:02:53+00:00 https://cessatech.com/wp-content/uploads/2021/08/Trial0206.png https://cessatech.com/first-us-patent-covering-ct001/ 2021-11-02T17:14:12+00:00 https://cessatech.com/wp-content/uploads/2021/11/US_flag.jpeg https://cessatech.com/exercise-warrants-of-series-to1-before-14-dec/ 2021-12-08T08:21:43+00:00 https://cessatech.com/wp-content/uploads/2021/11/ExerciseWarrants.jpg https://cessatech.com/cessatech-successfully-raises-approx-dkk-24-3-million-through-warrant-exercise/ 2021-12-23T08:01:05+00:00 https://cessatech.com/wp-content/uploads/2021/12/WarrantSuccess.jpeg https://cessatech.com/changes-to-the-board-of-directors-welcome-to-rachel/ 2022-01-07T10:03:12+00:00 https://cessatech.com/wp-content/uploads/2022/01/RachelCG-scaled.jpg https://cessatech.com/annual-report-2021-published/ 2022-03-03T13:10:29+00:00 https://cessatech.com/wp-content/uploads/2022/03/Screenshot-2022-03-03-at-14.03.17.png https://cessatech.com/physical-restraint-of-children-in-79-of-scandinavian-emergency-departments/ 2022-03-15T15:28:28+00:00 https://cessatech.com/wp-content/uploads/2022/03/ChildIV_pain.png https://cessatech.com/off-label-use-of-medication-in-children-continue-to-be-the-rule-rather-than-the-exception/ 2022-03-15T15:31:03+00:00 https://cessatech.com/wp-content/uploads/2022/03/ChildOffLabel.jpeg https://cessatech.com/first-quarter-report-q1-2022/ 2022-04-19T15:30:28+00:00 https://cessatech.com/wp-content/uploads/2022/04/Q1-2022.png https://cessatech.com/cessatech-reports-last-patient-dosed-in-pharmacokinetic-trial-in-children-of-lead-candidate/ 2022-05-16T06:15:52+00:00 https://cessatech.com/wp-content/uploads/2021/08/Trial0206.png https://cessatech.com/regulatory-green-light-for-trial-0205-the-pivotal-trial-for-ct001-first-patient-expected-shortly/ 2022-07-01T08:50:16+00:00 https://cessatech.com/wp-content/uploads/2022/06/Trial0205.png https://cessatech.com/second-quarter-report-q2-2022/ 2022-09-01T10:52:49+00:00 https://cessatech.com/wp-content/uploads/2022/09/Screenshot-2022-09-01-at-12.51.47.png https://cessatech.com/first-patient-dosed-in-pivotal-trial-of-lead-product-candidate/ 2022-09-05T15:35:57+00:00 https://cessatech.com/wp-content/uploads/2022/09/Trial0205.png https://cessatech.com/successful-outcome-of-pharmacokinetic-trial-in-children-of-lead-candidate/ 2022-09-23T07:50:25+00:00 https://cessatech.com/wp-content/uploads/2021/08/Trial0206.png https://cessatech.com/dkk-18-3-million-capital-raise-through-a-80-guarantee/ 2022-10-19T19:34:14+00:00 https://cessatech.com/wp-content/uploads/2020/09/AdobeStock_360221622_low2-scaled.jpeg https://cessatech.com/successful-outcome-of-rights-issue/ 2022-11-14T19:09:57+00:00 https://cessatech.com/wp-content/uploads/2021/12/WarrantSuccess.jpeg https://cessatech.com/third-quarter-report-q3-2022/ 2022-11-18T07:53:23+00:00 https://cessatech.com/wp-content/uploads/2022/11/Q3_2022-1.png https://cessatech.com/successful-outcome-from-trial-0204/ 2022-12-16T10:32:23+00:00 https://cessatech.com/wp-content/uploads/2022/03/Trial0204.png https://cessatech.com/annual-report-for-the-fiscal-year-2022/ 2023-03-02T18:00:44+00:00 https://cessatech.com/wp-content/uploads/2023/02/AR2022.png https://cessatech.com/cessatech-announces-new-chairman-of-the-board/ 2023-03-23T13:24:37+00:00 https://cessatech.com/wp-content/uploads/2023/03/Chair_BoD_MO.jpg https://cessatech.com/first-quarter-report-q1-2023/ 2023-05-17T04:40:47+00:00 https://cessatech.com/wp-content/uploads/2023/05/Q1-2023.png https://cessatech.com/wp-content/uploads/2023/05/2023-Q1-QA.jpg https://cessatech.com/cessatech-and-ventis-pharma-announce-us-partnership-for-ct001/ 2023-06-27T08:02:52+00:00 https://cessatech.com/wp-content/uploads/2023/06/US_post.jpg https://cessatech.com/second-quarter-report-q2-2023/ 2023-08-30T13:25:31+00:00 https://cessatech.com/wp-content/uploads/2023/08/Q2-2023_logo.png https://cessatech.com/1456-2/ 2023-08-31T10:58:04+00:00 https://cessatech.com/wp-content/uploads/2023/08/Figure_6-Managing_pain.jpg https://cessatech.com/cessatech-announces-agreement-with-the-european-medicines-agency-on-a-paediatric-investigational-plan-for-its-second-asset-ct002-for-medical-procedural-sedation-in-children/ 2023-09-12T07:09:57+00:00 https://cessatech.com/wp-content/uploads/2023/09/CT002_intro.png https://cessatech.com/positive-topline-data-from-study-0205-with-its-lead-candidate-ct001-for-the-treatment-of-pain-in-children-supporting-further-advancement-of-ct001/ 2023-12-26T12:13:20+00:00 https://cessatech.com/wp-content/uploads/2023/12/Study0205-1.png https://cessatech.com/cessatech-announces-that-the-paediatric-committee-has-agreed-to-a-50-reduction-of-the-required-number-of-patients-in-the-final-study-of-its-nasal-spray-for-the-treatment-of-acute-pain-in-children/ 2023-12-26T12:17:45+00:00 https://cessatech.com/wp-content/uploads/2023/10/Study0202.png https://cessatech.com/1484-2/ 2023-12-26T12:19:00+00:00 https://cessatech.com/wp-content/uploads/2023/12/Study0205-1.png https://cessatech.com/qa-session-topline-data-from-study-0205/ 2024-01-04T16:57:43+00:00 https://cessatech.com/wp-content/uploads/2023/12/Study0205-1.png https://cessatech.com/wp-content/uploads/2024/01/QA-study-0205_Q10.jpg https://cessatech.com/annual-report-2023/ 2024-02-29T08:03:11+00:00 https://cessatech.com/wp-content/uploads/2024/02/AR-Q4_2023-Report.jpg https://cessatech.com/cessatech-2024-major-milestones-and-focus/ 2024-04-04T16:57:35+00:00 https://cessatech.com/wp-content/uploads/2024/01/Cessatech-2024-focus.jpg https://cessatech.com/treating-children-is-not-just-like-treating-small-adults/ 2024-04-05T07:33:54+00:00 https://cessatech.com/wp-content/uploads/2024/04/Not-like-adults_CT.jpg https://cessatech.com/wp-content/uploads/2024/04/Not-like-adults_CT.jpg https://cessatech.com/august-business-update/ 2024-04-05T07:34:28+00:00 https://cessatech.com/wp-content/uploads/2023/08/Newsletter_august2023.png https://cessatech.com/acute-pain-treatment-large-unmet-need-paediatrics-receive-least-mainly-due-to-inadequate-solutions/ 2024-04-05T07:42:38+00:00 https://cessatech.com/wp-content/uploads/2024/04/Large-unmet-need_CT.jpg https://cessatech.com/wp-content/uploads/2024/04/Large-unmet-need_CT.jpg https://cessatech.com/cessatech-reports-first-patient-dosed-in-final-safety-study-0202-of-lead-product-candidate-ct001/ 2024-05-27T13:07:24+00:00 https://cessatech.com/wp-content/uploads/2024/05/Study0202-2.png https://cessatech.com/cessatech-announces-superior-simulated-pain-efficacy-in-children/ 2024-06-04T17:50:01+00:00 https://cessatech.com/wp-content/uploads/2024/06/WarrantSuccess.jpeg https://cessatech.com/new-data-on-paediatric-pain-relief-at-the-page-conference-in-rome-favouring-its-lead-candidate-ct001/ 2024-06-28T16:22:48+00:00 https://cessatech.com/wp-content/uploads/2024/06/Children.png https://cessatech.com/anders-dyhr-dombernowsky-toft-appointed-to-the-board-of-directors/ 2024-07-05T12:42:40+00:00 https://cessatech.com/wp-content/uploads/2024/07/Posts_AndersD.png https://cessatech.com/cessatech-extends-loan-facility-agreement-to-dkk-10-million/ 2024-08-12T09:56:12+00:00 https://cessatech.com/wp-content/uploads/2024/08/CT_LoanAgreement.jpg https://cessatech.com/cessatech-and-proveca-announce-world-wide-excluding-us-commercial-partnership-for-ct001/ 2024-08-27T08:04:52+00:00 https://cessatech.com/wp-content/uploads/2024/08/proveca-logo-en-strap-2.png https://cessatech.com/halfway-milestone-patient-recruitment-in-paediatric-study-0202/ 2024-11-12T09:25:11+00:00 https://cessatech.com/wp-content/uploads/2024/05/Study0202-2.png https://cessatech.com/positive-notified-body-opinion-under-mdr-for-ct001/ 2025-02-04T10:43:59+00:00 https://cessatech.com/wp-content/uploads/2025/02/EU-Medical-Device-Regulation-MDR-1024x768-1.png https://cessatech.com/annual-report-2024/ 2025-02-28T14:29:17+00:00 https://cessatech.com/wp-content/uploads/2025/02/AR2024_partnerships.png https://cessatech.com/positive-top-line-results-from-its-final-ct001-study-0202/ 2025-05-30T06:57:47+00:00 https://cessatech.com/wp-content/uploads/2025/05/CT001_0202_TL.png https://cessatech.com/strengthening-executive-management-with-the-promotion-of-martin-juhl/ 2025-06-20T08:43:05+00:00 https://cessatech.com/wp-content/uploads/2025/06/MartinJuhl_EM.jpg https://cessatech.com/marketing-authorisation-application-maa-for-ct001-has-been-submitted-to-the-european-medicines-agency-ema-for-acute-pain-management-in-children/ 2025-08-15T06:39:14+00:00 https://cessatech.com/wp-content/uploads/2025/08/Screenshot-2025-08-15-at-08.24.18.png https://cessatech.com/ct001-soon-available-for-us-hospitals-in-collaboration-with-staq-pharma-for-acute-pain-management-in-children/ 2025-11-25T09:09:03+00:00 https://cessatech.com/wp-content/uploads/2025/11/STAQ_Pharma.png https://cessatech.com/financial-report-q2-2025/ 2025-11-25T09:19:01+00:00 https://cessatech.com/wp-content/uploads/2025/11/Q2_2025.png https://cessatech.com/financial-report-q3-2025/ 2025-11-25T09:19:19+00:00 https://cessatech.com/wp-content/uploads/2025/11/Q3_2025.png https://cessatech.com/cessatech-qa-june-company-presentation/ 2025-11-25T09:28:31+00:00 https://cessatech.com/wp-content/uploads/2025/11/QA.png https://cessatech.com/wp-content/uploads/2025/06/QA-Cessatech_June-page-001.jpg https://cessatech.com/financial-report-q1-2025/ 2025-11-25T09:37:01+00:00 https://cessatech.com/wp-content/uploads/2025/11/Q1-2025.png https://cessatech.com/annual-general-meeting-in-cessatech-a-s/ 2025-11-25T09:46:09+00:00 https://cessatech.com/wp-content/uploads/2023/01/heart-icon.jpg https://cessatech.com/recruitment-has-completed-in-the-paediatric-study-0202/ 2025-11-25T09:50:06+00:00 https://cessatech.com/wp-content/uploads/2024/05/Study0202-2.png https://cessatech.com/children-deserve-better-prehospital-pain-treatment/ 2025-12-02T08:47:10+00:00 https://cessatech.com/wp-content/uploads/2025/12/63-children.jpg https://cessatech.com/completion-of-the-directed-issue-of-shares/ 2026-01-05T13:14:32+00:00 https://cessatech.com/wp-content/uploads/2024/06/WarrantSuccess.jpeg https://cessatech.com/paediatric-ed-pain-is-still-undertreated-the-need-for-training-and-more-treatment-options/ 2026-01-06T14:02:12+00:00 https://cessatech.com/wp-content/uploads/2026/01/Child-and-nurse-pain.jpg https://cessatech.com/paediatric-pain-in-the-ambulance-is-still-being-under-treated/ 2026-01-07T08:07:36+00:00 https://cessatech.com/wp-content/uploads/2026/01/Ped_transport-immediate-care.jpg https://cessatech.com/welcome-to/ 2026-02-02T11:01:50+00:00 https://cessatech.com/wp-content/uploads/2026/02/Welcome-to-Q1-2026.jpg https://cessatech.com/annual-report-for-2025/ 2026-02-27T07:29:44+00:00 https://cessatech.com/wp-content/uploads/2026/02/AR-Q4_2025-PR_image.jpg